Antares Pharma, Inc. provided revenue guidance for the year 2022. For the year, the company expects revenue to be range of $200 to $220 million, which does not include any unapproved products and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Excluding 2021 OTREXUP® proprietary revenue, the guidance range represents a 18% to 30% year-over-year growth rate.
Antares Pharma, Inc.
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.98% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
+13.95% | 25.02B |